1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Comparison of baseline characteristics according to clinical outcome
Poor Outcome (mRS > 2) (n = 60) Good Outcome (mRS ≤ 2) (n = 44) P Value
Age (yr) 74 (65–81) 66 (58–76) .005
Male (No.) (%) 33 (55.0%) 28 (63.6%) .424
Baseline NIHSS (mean) 16 ± 5 11 ± 6 <.001
Onset-to-needle time (mean) (min) 230 (168–297) 207 (119–259) .059
Endovascular thrombectomy (No.) (%) 22 (36.7%) 16 (36.4%) 1.000
Prior antiplatelet usage (No.) (%) 12 (20.0%) 9 (20.5%) 1.000
Risk factors
    Smoking (No.) (%) 18 (30.0%) 13 (29.5%) 1.000
    Hypertension (No.) (%) 35 (58.3%) 22 (50.0%) .431
    Diabetes mellitus (No.) (%) 16 (26.7%) 6 (13.6%) .146
    Hyperlipidemia (No.) (%) 22 (36.7%) 21 (47.7%) .315
    History of stroke/TIA (No.) (%) 11 (18.3%) 5 (11.4%) .415
    Atrial fibrillation (No.) (%) 38 (63.3%) 20 (45.5%) .076
Radiologic data 
    Baseline infarct core volume (mean) (mL) 69.27 ± 49.51 40.72 ± 30.91 .001
    Baseline hypoperfusion volume (mean) (mL) 134.28 ± 61.07 98.22 ± 60.43 .004
    TAI_max (median) (IQR) (HU) 18.0 (10.0–38.7) 39.9 (26.1–73.3) <.001
    TAI_peak (median) (IQR) (HU) 4.6 (−4.2–17.5) 18.7 (5.9–43.0) <.001
    TAI_con (median) (IQR) (HU) 2.2 (−5.5–12.4) 10.4 (−2.0–36.7) .006
    Thrombus perviousness by dichotomized TAI_max (No.) (%) 18 (30.0%) 31 (70.5%) <.001
    Thrombus perviousness by dichotomized TAI_peak (No.) (%) 22 (36.7%) 31 (70.5%) .001
    Thrombus perviousness by dichotomized TAI_con (No.) (%) 13 (21.7%) 21 (47.7%) .005